Armstrong, April W., Mark Lebwohl, Jerry Bagel, Todd Schlesinger, Subhashis Banerjee, Renata M. Kisa, Thomas Scharnitz, Kim Hoyt, and Bruce Strober. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)”. SKIN The Journal of Cutaneous Medicine 7, no. 2 (March 13, 2023): s120. Accessed July 3, 2024. https://jofskin.org/index.php/skin/article/view/1959.